CD274 and non-small cell lung carcinoma: Given various options for second-line treatment of advanced NSCLC, Aguiar et al. [22] assessed the cost-effectiveness and economic impact of PD-L1 testing and the above-mentioned three second-line ICIs versus docetaxel.